Early compliance and efficacy of sublingual immunotherapy in patients with allergic rhinitis for house dust mites

Clinical and Experimental Otorhinolaryngology

Volumn 2, Issue 3, 2009, Pages 136-140

  Chang, Hyun ^a   Han, Doo Hee ^a,b   Mo, Ji Hun ^a   Kim, Jeong Whun ^a,b   Kim, Dong Young ^a,b   Lee, Chul Hee ^a,b   Min, Yang Gi ^a,b   Rhee, Chae Seo ^b,c,d  

^a Seoul National University College of Medicine   (South Korea)

^b Institute of Allergy and Clinical Immunology   (South Korea)

^c Seoul National University   (South Korea)

^d Seoul National University Hospital   (South Korea)

Author keywords

Allergic rhinitis; Compliance; Immunotherapy

Indexed keywords

EID: 70349631978     PISSN: 19768710     EISSN: 20050720     Source Type: Journal    
DOI: 10.3342/ceo.2009.2.3.136     Document Type: Article

References (22)

1. Esch RE. Sublingual immunotherapy. Curr Opin Otolaryngol Head Neck Surg. 2008 Jun;16(3):260-264.
2. Guez S, Vatrinet C, Fadel R, Andre C. House-dust-mite sublingualswallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy. 2000 Apr;55(4):369-375.
3. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr;63 Suppl 86:8-160.
4. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2003;(2):CD002893.
5. Casanovas M, Guerra F, Moreno C, Miguel R, Maranon F, Daza JC. Double-blind, placebo-controlled clinical trial of preseasonal treatment with allergenic extracts of Olea europaea pollen administered sublingually. J Investig Allergol Clin Immunol. 1994 Nov-Dec;4(6):305-314.
6. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol. 1996 Jun;97(6):1356-1365.
7. Pradalier A, Basset D, Claudel A, Couturier P, Wessel F, Galvain S, et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy. 1999 Aug;54(8):819-828.
8. Purello-D'Ambrosio F, Gangemi S, Isola S, La Motta N, Puccinelli P, Parmiani S, et al. Sublingual immunotherapy: a double-blind, placebocontrolled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy. 1999 Sep; 54(9):968-973.
9. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006 Aug;118(2):434-440.
10. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006 Apr;117(4):802-809.
11. Nuhoglu Y, Ozumut SS, Ozdemir C, Ozdemir M, Nuhoglu C, Erguven M. Sublingual immunotherapy to house dust mite in pediatric patients with allergic rhinitis and asthma: a retrospective analysis of clinical course over a 3-year follow-up period. J Investig Allergol Clin Immunol. 2007; 17(6):375-378.
12. Passalacqua G, Guerra L, Pasquali M, Canonica GW. Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy. Inflamm Allergy Drug Targets. 2006 Jan;5(1):43-51.
13. Kim DY, Kwon BW, Son JY. Assessment of satisfaction in patients undergoing immunotherapy for allergic rhinitis using questionnaires. Korean J Otolaryngol-Head Neck Surg. 2004 Feb;47(2):132-138.
14. Frew AJ. Sublingual immunotherapy. N Engl J Med. 2008 May;358 (21):2259-2264.
15. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy. 2006 Oct;61(10):1236-1237.
16. Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy. 2006 Oct;61(10):1235.
17. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy. 2007 May; 62(5):567-568.
18. Canonica GW, Passalacqua G. Sublingual immunotherapy in the treatment of adult allergic rhinitis patients. Allergy. 2006;61 Suppl 81:20-23.
19. Lombardi C, Gargioni S, Melchiorre A, Tiri A, Falagiani P, Canonica GW, et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. Allergy. 2001 Oct;56(10):989-992.
20. Rienzo VD, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica WG, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy. 2005 May;35(5):560-564.
21. Roder E, Berger MY, de Groot H, Gerth van Wijk R. Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial. Clin Exp Allergy. 2008 Oct;38(10):1659-1667.
22. Passalacqua G, Musarra A, Pecora S, Amoroso S, Antonicelli L, Cadario G, et al. Quantitative assessment of the compliance with a oncedaily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year). J Allergy Clin Immunol. 2006 Apr;117(4):946-948.